Angiotensin converting enzyme inhibitors remain the first treatment of choice

참고문헌 (19)

1. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), "ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation", Eur Heart J, 33, pp.2569~2619 (2012)
2. O’Gara PT, "2013 ACCF", AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation, Circulation, pp.2013, 127[DOI]
3. Strauss MH, "Angiotensin receptor blockers may increase risk of myocardial infarction : unraveling the ARB-MI paradox", Circulation, 114, pp.838~854 (2006)
4. Tsuyuki RT, "Angiotensin receptor blockers do not increase risk of myocardial infarction", Circulation, 114, pp.855~860 (2006)
5. Jang Hoon Lee, "Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction", The Korean Journal of Internal Medicine, 31(2), pp.267~276 (2016), 대한내과학회[DOI]
6. Yang JH, "Angiotensin receptor blocker in patients with ST segment elevation myocardial infarction with preserved left ventricular systolic function: prospective cohort study", BMJ, 349, pp.g6650~ (2014)
7. Koh KK, "Vascular and metabolic effects of candesartan: insights from therapeutic interventions", J Hypertens Suppl, 24, pp.S31~S38 (2006)
8. Koh KK, "Does reversal of oxidative stress and inflammation provide vascular protection?", Cardiovasc Res, 81, pp.649~659 (2009)
9. Koh KK, "Mechanism by which quinapril improves vascular function in coronary artery disease", Am J Cardiol, 83, pp.327~331 (1999)
10. Yusuf S, "Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions", Lancet, 340, pp.1173~1178 (1992)
11. Bosch J, "Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension", Circulation, 112, pp.1339~1346 (2005)
12. van Vark LC, "Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensin-aldosterone system inhibitors involving 158,998 patients", Eur Heart J, 33, pp.2088~2097 (2012)
13. Koh KK, "Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients", J Am Coll Cardiol, 42, pp.905~910 (2003)
14. 김지원, "Effect of High Dose Rosuvastatin Loading before Primary Percutaneous Coronary Intervention on Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction", Korean Circulation Journal, 44(2), pp.76~81 (2014), 대한심장학회
15. Lim S, "Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality", Int J Cardiol, 167, pp.1696~1702 (2013)
16. Koh KK, "Renin-angiotensin system inhibitor and statins combination therapeutics: what have we learnt?", Expert Opin Pharmacother, 16, pp.949~953 (2015)
17. Koh KK, "Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes", Hypertension, 45, pp.1088~1093 (2005)
18. Koh KK, "Combination pravastatin and valsartan treatment has additive beneficial effects to simultaneously improve both metabolic and cardiovascular phenotypes beyond that of monotherapy with either drug in patients with primary hypercholesterolemia", Diabetes, 62, pp.3547~3552 (2013)
19. 장지영, "Additive Beneficial Effects of Valsartan Combined with Rosuvastatin in the Treatment of Hypercholesterolemic Hypertensive Patients", Korean Circulation Journal, 45(3), pp.225~233 (2015), 대한심장학회

관련 논문AI추천